[go: up one dir, main page]

NO20024980L - Farmasöytiske formuleringer for törrpulverinhalatorer i form av harde pelleter - Google Patents

Farmasöytiske formuleringer for törrpulverinhalatorer i form av harde pelleter

Info

Publication number
NO20024980L
NO20024980L NO20024980A NO20024980A NO20024980L NO 20024980 L NO20024980 L NO 20024980L NO 20024980 A NO20024980 A NO 20024980A NO 20024980 A NO20024980 A NO 20024980A NO 20024980 L NO20024980 L NO 20024980L
Authority
NO
Norway
Prior art keywords
dry powder
fraction
powder
pharmaceutical formulations
fine particle
Prior art date
Application number
NO20024980A
Other languages
English (en)
Other versions
NO20024980D0 (no
NO332025B1 (no
Inventor
John Nicholas Staniforth
David Alexander Vodden Morton
Rajbir Gill
Gaetano Brambilla
Rossella Musa
Lorenzo Ferrarini
Original Assignee
Chiesi Farma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26071084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20024980(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB0009469.8A external-priority patent/GB0009469D0/en
Application filed by Chiesi Farma Spa filed Critical Chiesi Farma Spa
Publication of NO20024980D0 publication Critical patent/NO20024980D0/no
Publication of NO20024980L publication Critical patent/NO20024980L/no
Publication of NO332025B1 publication Critical patent/NO332025B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Otolaryngology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
NO20024980A 2000-04-17 2002-10-16 Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter NO332025B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0009469.8A GB0009469D0 (en) 2000-04-17 2000-04-17 Improvements in or relating to formalities for use in inhaler devices
EP00113608 2000-06-27
PCT/EP2001/004338 WO2001078693A2 (en) 2000-04-17 2001-04-17 Pharmaceutical formulations for dry powder inhalers in the form of hard-pellets

Publications (3)

Publication Number Publication Date
NO20024980D0 NO20024980D0 (no) 2002-10-16
NO20024980L true NO20024980L (no) 2002-12-17
NO332025B1 NO332025B1 (no) 2012-05-29

Family

ID=26071084

Family Applications (4)

Application Number Title Priority Date Filing Date
NO20024980A NO332025B1 (no) 2000-04-17 2002-10-16 Farmasoytiske formuleringer for torrpulverinhalatorer i form av harde pelleter
NO20024973A NO342999B1 (no) 2000-04-17 2002-10-16 Pulver for bruk i en tørrpulverinhalator, samt fremgangsmåte for fremstilling derav
NO20024971A NO20024971L (no) 2000-04-17 2002-10-16 Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger
NO20110885A NO336687B1 (no) 2000-04-17 2011-06-20 Farmasøytiske formuleringer for tørt pulverinhalatorer i form av harde pelleter

Family Applications After (3)

Application Number Title Priority Date Filing Date
NO20024973A NO342999B1 (no) 2000-04-17 2002-10-16 Pulver for bruk i en tørrpulverinhalator, samt fremgangsmåte for fremstilling derav
NO20024971A NO20024971L (no) 2000-04-17 2002-10-16 Forbedringer av formuleringer for anvendelse i inhaleringsinnretninger
NO20110885A NO336687B1 (no) 2000-04-17 2011-06-20 Farmasøytiske formuleringer for tørt pulverinhalatorer i form av harde pelleter

Country Status (32)

Country Link
US (4) US6884794B2 (no)
EP (6) EP1276473B1 (no)
JP (2) JP2003530425A (no)
KR (1) KR20030069047A (no)
CN (1) CN1424909A (no)
AT (5) ATE348603T1 (no)
AU (3) AU4859501A (no)
BR (3) BR0110139A (no)
CA (3) CA2406201C (no)
CY (1) CY1107315T1 (no)
CZ (1) CZ301904B6 (no)
DE (3) DE60123031T2 (no)
DK (3) DK1719505T3 (no)
DZ (1) DZ3315A1 (no)
EE (1) EE05257B1 (no)
ES (3) ES2292576T3 (no)
GB (2) GB2363988A (no)
HU (4) HU229270B1 (no)
IL (1) IL152306A0 (no)
MA (1) MA26892A1 (no)
MX (3) MXPA02010212A (no)
MY (1) MY129384A (no)
NO (4) NO332025B1 (no)
NZ (1) NZ521887A (no)
PE (1) PE20011227A1 (no)
PL (3) PL204213B1 (no)
PT (3) PT1276472E (no)
SA (1) SA01220062B1 (no)
SI (2) SI1719505T1 (no)
SK (1) SK284248B6 (no)
TN (1) TNSN01060A1 (no)
WO (3) WO2001078694A2 (no)

Families Citing this family (170)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) * 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
US20070212422A1 (en) * 1999-11-10 2007-09-13 Manfred Keller Dry powder for inhalation
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
EP1158958B1 (en) * 1999-03-05 2007-06-06 CHIESI FARMACEUTICI S.p.A. Improved powdery pharmaceutical compositions for inhalation
IT1309592B1 (it) * 1999-03-05 2002-01-24 Chiesi Farma Spa Particelle veicolo modificate da utilizzarsi nella preparazione diformulazioni farmaceutiche sotto forma di polimeri per inalazione e
GB0009469D0 (en) 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0012260D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel composition
GB0012261D0 (en) 2000-05-19 2000-07-12 Astrazeneca Ab Novel process
EP1296651B2 (en) 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
DK1337240T4 (en) * 2000-11-30 2015-01-05 Vectura Ltd A process for the preparation of particles for use in a pharmaceutical composition
EP1337239B2 (en) * 2000-11-30 2015-11-25 Vectura Limited Particles for use in a pharmaceutical composition
DK2283818T3 (en) † 2000-11-30 2017-10-16 Vectura Ltd Process for preparing particles for use in a pharmaceutical composition
WO2002056948A1 (en) 2001-01-17 2002-07-25 Vectura Limited An inhaler device
GB0208742D0 (en) 2002-04-17 2002-05-29 Bradford Particle Design Ltd Particulate materials
WO2003024396A2 (en) 2001-09-17 2003-03-27 Glaxo Group Limited Dry powder medicament formulations
US7931533B2 (en) 2001-09-28 2011-04-26 Igt Game development architecture that decouples the game logic from the graphics logics
SE0200312D0 (sv) 2002-02-01 2002-02-01 Astrazeneca Ab Novel composition
AU2002330390A1 (en) * 2002-03-20 2003-09-29 Hosokawa Micron Corporation Method of manufacturing chemical-containing composite particles
FI116657B (fi) * 2002-03-28 2006-01-31 Focus Inhalation Oy Menetelmä kantoainehiukkasten käsittelemiseksi ja niiden käyttö
US20030235538A1 (en) * 2002-04-09 2003-12-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Method for the administration of an anticholinergic by inhalation
US7582284B2 (en) * 2002-04-17 2009-09-01 Nektar Therapeutics Particulate materials
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
NZ538965A (en) * 2002-08-21 2006-11-30 Norton Healthcare Ltd Dry powder inhalation compositions
AU2003263717A1 (en) * 2002-09-25 2004-04-19 Astrazeneca Ab A COMBINATION OF A LONG-ACTING Beta2-AGONIST AND A GLUCOCORTICOSTEROID IN THE TREATMENT OF FIBROTIC DISEASES
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
EP1452179A1 (en) * 2003-02-27 2004-09-01 CHIESI FARMACEUTICI S.p.A. Novel medicament combination of a highly potent long-lasting beta2-agonist and a corticosteroid
JP2006522634A (ja) * 2003-04-14 2006-10-05 ベクトゥラ・リミテッド 投与効率を向上させるデバイス及び製薬組成
US20060147389A1 (en) * 2004-04-14 2006-07-06 Vectura Ltd. Devices and pharmaceutical compositions for enhancing dosing efficiency
US7094545B2 (en) * 2003-04-30 2006-08-22 Ferring Bv Pharmaceutical composition as solid dosage form and method for manufacturing thereof
WO2005004845A1 (en) * 2003-07-11 2005-01-20 Glaxo Group Limited Pharmaceutical formulations comprising magnesium stearate
EP1646370A1 (en) * 2003-07-11 2006-04-19 Glaxo Group Limited Pharmaceutical formulations
CN1826099B (zh) * 2003-07-25 2010-06-09 凡林有限公司 固体剂型药物组合物及其制造方法
EP1500390B1 (en) 2003-07-25 2005-08-17 Ferring B.V. Pharmaceutical desmopressin composition as solid dosage form and method for manufacturing thereof
US20060292081A1 (en) * 2003-09-15 2006-12-28 Vectura Limited Methods for preparing pharmaceutical compositions
GB0327723D0 (en) * 2003-09-15 2003-12-31 Vectura Ltd Pharmaceutical compositions
GB0321607D0 (en) 2003-09-15 2003-10-15 Vectura Ltd Manufacture of pharmaceutical compositions
GB0324918D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Composition
GB0326632D0 (en) * 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
SE0303569L (sv) * 2003-12-03 2005-06-04 Microdrug Ag DPI för avlämning av fuktkänsliga medikament
SE0303570L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Fukt-känslig medicinsk produkt
SE0303270L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Metod för administration av tiotropium
CA2547782A1 (en) * 2003-12-03 2005-06-16 Microdrug Ag Medical product containing tiotropium
SE0303269L (sv) * 2003-12-03 2005-06-04 Microdrug Ag Medicinsk produkt
SE0303571D0 (sv) * 2003-12-03 2003-12-22 Microdrug Ag Medical product for moisture-sensitive medicaments
US7018653B2 (en) 2003-12-29 2006-03-28 Ferring B.V. Method for preparing solid dosage form of desmopressin
JO3102B1 (ar) 2004-03-17 2017-09-20 Chiesi Framaceutici S P A صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
ES2909080T3 (es) 2004-04-23 2022-05-05 Cydex Pharmaceuticals Inc Formulación de DPI que contiene sulfoalquil éter ciclodextrina
GB0409703D0 (en) 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
GB0426301D0 (en) * 2004-11-30 2004-12-29 Vectura Ltd Pharmaceutical formulations
NZ556709A (en) 2005-02-10 2009-09-25 Glaxo Group Ltd Process for making lactose utilizing pre-classification techniques and pharmaceutical formulations formed therefrom
BRPI0608844A2 (pt) * 2005-03-09 2010-02-02 Ono Pharmaceutical Co partìcula e preparação que contém a partìcula
EP2484382A1 (en) * 2005-03-30 2012-08-08 Schering Corporation Medicament comprising a phosphodiesterase IV inhibitor in an inhalable form
TWI274641B (en) * 2005-08-30 2007-03-01 Rexon Ind Corp Ltd Cutting machine
US7629331B2 (en) 2005-10-26 2009-12-08 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions and methods of preparation thereof
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
GB0613161D0 (en) * 2006-06-30 2006-08-09 Novartis Ag Organic Compounds
GB0622818D0 (en) * 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
EP1944018A1 (en) * 2007-01-10 2008-07-16 CHIESI FARMACEUTICI S.p.A. Micronised particles of low-dosage strength active agents for powder formulations for inhalation
ES2691033T3 (es) 2007-02-11 2018-11-23 Map Pharmaceuticals Inc. Método de administración terapéutica de DHE para activar el alivio rápido de la migraña a la vez que se reduce al mínimo el perfil de los efectos secundarios
EP2176251B1 (en) 2007-07-21 2012-02-08 Albany Molecular Research, Inc. 5-pyridinone substituted indazoles and pharmaceutical compositions thereof
EP2222639A1 (en) 2007-11-21 2010-09-01 Decode Genetics EHF Biaryl pde4 inhibitors for treating pulmonary and cardiovascular disorders
EP2292089A1 (en) 2008-01-11 2011-03-09 Astellas Pharma Inc. Model animal having both pain in testis or testis-related discomfort actions and frequent urination
EP2240481A1 (en) 2008-01-11 2010-10-20 Albany Molecular Research, Inc. (1-azinone) -substituted pyridoindoles as mch antagonists
EP2080508A1 (en) 2008-01-15 2009-07-22 CHIESI FARMACEUTICI S.p.A. Dry powder formulation comprising an anticholinergic drug
WO2010059836A1 (en) 2008-11-20 2010-05-27 Decode Genetics Ehf Substituted aza-bridged bicyclics for cardiovascular and cns disease
EP2191821A1 (en) * 2008-11-26 2010-06-02 CHIESI FARMACEUTICI S.p.A. Microparticles comprising a salt of 8-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone having improved adhesion properties for dry powder inhalation
CN102361876B (zh) 2009-01-26 2015-02-04 以色列生物研究所 二环杂环螺环化合物
US9925282B2 (en) 2009-01-29 2018-03-27 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
WO2010097188A1 (en) 2009-02-25 2010-09-02 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a salt of carmoterol and a corticosteroid
ES2739352T3 (es) 2009-02-26 2020-01-30 Glaxo Group Ltd Formulaciones farmacéuticas que comprenden 4-{(1R)-2-[(6-{2-[(2,6-diclorobencil)oxi]etoxi}hexil)amino]-1-hidroxietil}-2-(hidroximetil)fenol
CN102458372A (zh) * 2009-04-24 2012-05-16 先灵公司 适用在干粉吸入器中的聚结物制剂
WO2011015289A1 (en) 2009-08-04 2011-02-10 Chiesi Farmaceutici S.P.A. 8-hydroxy-5-[(1r)-1-hydroxy-2-[[(1r)-2-(4-methoxyphenyl)-1-methylethyl] amino]ethyl]-2(1h)-quinolinone hemi-fumarate
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
GB0921075D0 (en) 2009-12-01 2010-01-13 Glaxo Group Ltd Novel combination of the therapeutic agents
EP2360147A1 (en) 2010-02-22 2011-08-24 CHIESI FARMACEUTICI S.p.A. Process for preparing crystalline particles of a salt of 8-hydroxy-5-[(1R)-1-hydroxy-2-[[(1R)-2-(4-methoxyphenyl)-1-methylethyl]amino] ethyl]-2(1H)-quinolinone (carmoterol)
BR112012024059B1 (pt) 2010-04-01 2021-06-01 Chiesi Farmaceutici S.P.A. Processo de preparo de um excipiente para composições farmacêuticas em pó para inalação, partículas carreadoras para uma formulação farmacêutica de pó seco, composição farmacêutica em forma de pó seco para inalação e inalador de pó seco
KR20130062268A (ko) * 2010-04-21 2013-06-12 키에시 파르마슈티시 엣스. 피. 에이. 정전하가 감소된 입자를 제공하는 방법
KR101800913B1 (ko) 2010-04-30 2017-12-20 알렉시온 파마슈티칼스, 인코포레이티드 항-c5a 항체들과 이 항체들을 이용하는 방법
EP2575786B1 (en) 2010-06-03 2017-11-15 Sima Patent ve Lisanslama Hizmetleri Ltd.Sti. Process for dry powder formulations
CN102946868B (zh) 2010-06-22 2014-10-29 奇斯药制品公司 包含抗毒蕈碱药的干粉制剂
GEP20156343B (en) * 2010-08-03 2015-08-10 Chiesi Farma Spa Dry powder formulation comprising a phosphodiesterase inhibitor
EP2611416B1 (en) * 2010-09-03 2015-08-19 Pharmaterials Ltd. Pharmaceutical composition suitable for use in a dry powder inhaler
CA3086367A1 (en) 2010-09-29 2012-04-05 Pulmatrix Operating Company, Inc. Monovalent metal cation dry powders for inhalation
CA2813096C (en) 2010-09-30 2019-10-29 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
MX350838B (es) 2011-02-11 2017-09-18 Grain Proc Corporation * Composicion de sal.
TR201105367A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Akış özellikleri geliştirilmiş bir kuru toz formülasyonu.
TR201205852A2 (tr) * 2011-06-02 2012-12-21 Bi̇lgi̇ç Mahmut Geliştirilmiş yeni kuru toz formülasyonu.
WO2013109215A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising formoterol
WO2013109211A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising r-formoterol as active agent
WO2013109214A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Process for the preparation of dry powder formulations
FI3412277T3 (fi) 2012-01-25 2023-03-23 Chiesi Farm Spa Kortikosteroidia ja beeta-adrenergista ainetta käsittävä kuivajauheformulaatio annettavaksi inhalaatiolla
US9603907B2 (en) 2012-02-01 2017-03-28 Protalix Ltd. Dry powder formulations of dNase I
CN104487075A (zh) 2012-02-29 2015-04-01 普马特里克斯公司 可吸入干粉剂
EP3421042B1 (en) 2012-03-07 2024-04-17 Beyond Air Ltd Inhalation of nitric oxide for treating respiratory diseases
KR20140131971A (ko) 2012-03-13 2014-11-14 레스피버트 리미티드 신규 약학 제제
ES2814336T3 (es) 2012-04-13 2021-03-26 Glaxosmithkline Ip Dev Ltd Partículas de agregado
WO2014007772A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising glucose anhydrous
US10105316B2 (en) 2012-07-05 2018-10-23 Arven llac Sanayi Ve Ticaret A.S. Inhalation compositions comprising muscarinic receptor antagonist
US9855276B2 (en) 2012-10-25 2018-01-02 The General Hospital Corporation Combination therapies for the treatment of Alzheimer's disease and related disorders
US11052202B2 (en) 2012-11-07 2021-07-06 Chiesi Farmaceutici S.P.A. Drug delivery device for the treatment of patients with respiratory diseases
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP2948148B1 (en) 2013-01-28 2020-07-29 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
GB201305825D0 (en) 2013-03-28 2013-05-15 Vectura Ltd New use
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
US10525005B2 (en) 2013-05-23 2020-01-07 The General Hospital Corporation Cromolyn compositions and methods thereof
EP2821062A1 (en) * 2013-07-01 2015-01-07 Arven Ilac Sanayi Ve Ticaret A.S. Novel dry powder inhaler formulations
PT3019153T (pt) * 2013-07-11 2018-12-04 Chiesi Farm Spa Formulação de pó seco que compreende um anticolinérgico, um corticosteroide e um beta-adrenérgico para administração por inalação
EP3052092A2 (en) * 2013-10-02 2016-08-10 Vectura Limited Method and apparatus
US9427376B2 (en) 2013-10-10 2016-08-30 Chiesi Farmaceutici S.P.A. Process for preparing pharmaceutical formulations for inhalation comprising a high-dosage strength active ingredient
EP3060205A4 (en) 2013-10-22 2017-06-28 The General Hospital Corporation Cromolyn derivatives and related methods of imaging and treatment
NZ631007A (en) 2014-03-07 2015-10-30 Alexion Pharma Inc Anti-c5 antibodies having improved pharmacokinetics
US9554992B2 (en) 2014-06-09 2017-01-31 Chiesi Farmaceutici S.P.A. Inhalation particles comprising a combination of an anticholinergic, a corticosteroid and a beta-adrenergic
EP2957552B1 (en) 2014-06-16 2020-01-22 Arven Ilac Sanayi Ve Ticaret A.S. Vilanterol formulations
TR201407010A2 (tr) 2014-06-16 2015-12-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Vilanterol formülasyonları.
TR201818680T4 (tr) * 2014-07-09 2019-01-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi İnhalasyona yönelik formülasyonların hazırlanması için bir proses.
US20170304459A1 (en) 2014-10-10 2017-10-26 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhalation delivery of conjugated oligonucleotide
CA2965759C (en) 2014-10-31 2023-12-12 Glaxosmithkline Intellectual Property Development Limited Powdered polypeptides with decreased disulfide impurities comprising divalent cationic materials
RU2693201C1 (ru) * 2015-06-23 2019-07-01 Шлюмберже Текнолоджи Б.В. Распознание расклинивающего агента с помощью мобильного устройства
US11224594B2 (en) * 2015-09-16 2022-01-18 Philip Morris Products S.A. Nicotine formulations and methods of making and using the same
HRP20200571T1 (hr) * 2015-11-16 2020-07-10 Chiesi Farmaceutici S.P.A. Postupak priprave formulacije suhog praška koji sadrži antikolinergik, kortikosteroid i beta-adrenergik
TWI731891B (zh) 2015-11-16 2021-07-01 義大利商吉斯藥品公司 含有抗膽鹼劑、皮質類固醇及β-腎上腺素之乾粉配方之製備方法
SG11201805204WA (en) 2015-12-24 2018-07-30 Philip Morris Products Sa Nicotine particle capsule
JP2019517473A (ja) 2016-05-27 2019-06-24 アレクシオン ファーマシューティカルズ インコーポレイテッドＡｌｅｘｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 難治性全身型重症筋無力症の処置のための方法
CN116889562A (zh) 2016-08-31 2023-10-17 通用医疗公司 与神经退行性疾病相关的神经炎症中的巨噬细胞/小胶质细胞
CN110582269B (zh) * 2017-05-11 2023-02-28 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
KR20220155609A (ko) 2017-05-11 2022-11-23 키에시 파르마슈티시 엣스. 피. 에이. 항콜린제, 코르티코스테로이드 및 베타-아드레날린성 약물을 포함하는 건조 분말 제제의 제조 방법
US10583085B2 (en) * 2017-05-17 2020-03-10 Chiesi Farmaceutici S.P.A. Carrier particles for dry powder formulations for inhalation
US11220544B2 (en) 2017-07-14 2022-01-11 Cytomx Therapeutics, Inc. Anti-CD166 antibodies and uses thereof
EP3658033A4 (en) * 2017-07-26 2021-02-24 Shenzhen Xpectvision Technology Co., Ltd. SYSTEM WITH A SPATIAL EXTENSION X-RAY SOURCE FOR X-RAY IMAGING
ES2965486T3 (es) 2017-07-27 2024-04-15 Alexion Pharma Inc Formulaciones de anticuerpos anti-C5 de alta concentración
WO2019060604A1 (en) 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE MEDICINE
CN115919780A (zh) * 2017-09-22 2023-04-07 维克图拉公司 含有硬脂酸镁的干粉组合物
WO2019060797A1 (en) 2017-09-22 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. PROCESS FOR PRODUCING POWDERS FOR INHALING
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
WO2019067708A1 (en) * 2017-09-27 2019-04-04 Teva Branded Pharmaceutical Products R&D, Inc. METHOD FOR DECREASING PARTICLE SIZE
KR20200070355A (ko) 2017-10-26 2020-06-17 알렉시온 파마슈티칼스, 인코포레이티드 발작성 야간 혈색소뇨 (pnh) 및 비정형 용혈성 요독 증후군 (ahus)의 치료를 위한 항-c5 항체의 투여량 및 투여
ES2996257T3 (en) 2018-05-31 2025-02-12 Alexion Pharma Inc Dosage and administration of anti-c5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (pnh) in pediatric patients
EP3802603A1 (en) 2018-06-04 2021-04-14 Alexion Pharmaceuticals, Inc. Dosage and administration of anti-c5 antibodies for treatment of atypical hemolytic uremic syndrome (ahus) in pediatric patients
WO2020006266A1 (en) 2018-06-28 2020-01-02 Alexion Pharmaceuticals, Inc. Methods of producing anti-c5 antibodies
CA3105392A1 (en) * 2018-07-02 2020-01-09 The General Hospital Corporation Powdered formulations of cromolyn sodium and .alpha.-lactose
AU2019311268B2 (en) 2018-07-27 2025-01-16 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
WO2020049505A1 (en) 2018-09-06 2020-03-12 Innopharmascreen Inc. Methods and compositions for treatment of asthma or parkinson's disease
US12240893B2 (en) 2018-10-30 2025-03-04 Alexion Pharmaceuticals, Inc. Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
CN112969490B (zh) 2018-10-30 2024-07-12 奇斯药制品公司 用于向机械辅助呼吸患者施用药物的设备
AU2019397436A1 (en) 2018-12-10 2021-07-22 The General Hospital Corporation Cromolyn esters and uses thereof
IL283734B2 (en) 2018-12-12 2025-03-01 Kite Pharma Inc Chimeric antigen receptors and CAR-T cells and methods of use
KR20220002600A (ko) 2019-04-29 2022-01-06 인스메드 인코포레이티드 트레프로스티닐 전구약물의 건조 분말 조성물 및 이의 사용 방법
WO2021058454A1 (en) 2019-09-24 2021-04-01 Chiesi Farmaceutici S.P.A. Novel carrier particles for dry powder formulations for inhalation
WO2021207060A1 (en) 2020-04-06 2021-10-14 The General Hospital Corporation Methods of treatment of coronavirus-induced inflammation conditions
BR112022021450A2 (pt) 2020-04-24 2022-12-27 Millennium Pharm Inc O cd19 ou fragmento de ligação, método de tratamento de um câncer, composição farmacêutica, ácido nucleico, vetor, e, célula isolada
US20230277524A1 (en) 2020-05-22 2023-09-07 Trailhead Biosystems Inc. Combination therapy for treatment of viral infections
CN112451509B (zh) * 2020-12-19 2023-03-07 沈阳药科大学 一种川丁特罗吸入粉雾剂及其制备方法
CN117425673A (zh) 2021-04-09 2024-01-19 武田药品工业株式会社 靶向补体因子d的抗体和其用途
MX2023011712A (es) 2021-04-26 2023-10-12 Millennium Pharm Inc Anticuerpos anti receptor de adhesion acoplado a proteinas g e2 (adgre2) y usos de los mismos.
KR20240004286A (ko) 2021-04-26 2024-01-11 밀레니엄 파머슈티컬스 인코퍼레이티드 항 Clec12A 항체 및 이의 용도
WO2023068382A2 (en) 2021-10-20 2023-04-27 Takeda Pharmaceutical Company Limited Compositions targeting bcma and methods of use thereof
WO2023117967A1 (en) 2021-12-21 2023-06-29 Chiesi Farmaceutici S.P.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
EP4452223A1 (en) 2021-12-21 2024-10-30 Chiesi Farmaceutici S.p.A. Dry powder formulations filled in an inhaler with improved resistance to humidity
WO2023150747A1 (en) 2022-02-07 2023-08-10 Insmed Incorporated Dry powder compositions of bedaquiline and salts and methods of use thereof
CA3268243A1 (en) 2022-09-22 2024-03-28 Chiesi Farm Spa CAPSULE INHALATOR FOR THE ADMINISTRATION OF A PHOSPHODIESTERASE-4 INHIBITOR

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1242211A (en) 1967-08-08 1971-08-11 Fisons Pharmaceuticals Ltd Pharmaceutical composition
GB1381872A (en) 1971-06-22 1975-01-29 Fisons Ltd Pharmaceutical compositions for inhalation
GB1520247A (en) 1974-08-10 1978-08-02 Fisons Ltd Pelletised medicament formulations
GB1571629A (en) 1977-11-30 1980-07-16 Fisons Ltd Pharmaceutical compositions containing beclomethasone dipropionate
US4349542A (en) * 1979-06-08 1982-09-14 National Research Development Corporation Mixture containing active ingredient and dendritic crystalline sugar for tableting
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
US5376386A (en) * 1990-01-24 1994-12-27 British Technology Group Limited Aerosol carriers
DE59100388D1 (de) 1990-01-29 1993-10-28 Ciba Geigy Verfahren und Vorrichtung zur Dosierung eines feinkörnigen Pulvers.
DE4140689B4 (de) 1991-12-10 2007-11-22 Boehringer Ingelheim Kg Inhalationspulver und Verfahren zu ihrer Herstellung
US5626871A (en) 1992-06-12 1997-05-06 Teijin Limited Preparation for intratracheobronchial administration
GB2269992A (en) 1992-08-14 1994-03-02 Rh Ne Poulenc Rorer Limited Powder inhalation formulations
GB9322014D0 (en) 1993-10-26 1993-12-15 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
DE4425255A1 (de) * 1994-07-16 1996-01-18 Asta Medica Ag Formulierung zur inhalativen Applikation
SE9700134D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
SE9700136D0 (sv) 1997-01-20 1997-01-20 Astra Ab New formulation
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
GB9515182D0 (en) 1995-07-24 1995-09-20 Co Ordinated Drug Dev Improvements in and relating to powders for use in dry powder inhalers
US6565885B1 (en) * 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
WO1999016541A1 (en) * 1997-09-30 1999-04-08 Mortimer Technology Holdings Ltd. A process and apparatus for treating particulate matter
EP1066074A1 (en) * 1998-03-16 2001-01-10 Inhale Therapeutic Systems, Inc. Aerosolized active agent delivery
DK1131059T3 (da) 1998-11-13 2003-06-30 Jago Res Ag Tørpulver til inhalation
GB9826783D0 (en) * 1998-12-04 1999-01-27 Scherer Ltd R P Inhalation powders
EP1158958B1 (en) * 1999-03-05 2007-06-06 CHIESI FARMACEUTICI S.p.A. Improved powdery pharmaceutical compositions for inhalation
CN1188111C (zh) * 1999-10-29 2005-02-09 耐科塔医药公司 分散性得到改进的干粉组合物
GB0009469D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formalities for use in inhaler devices
PE20011227A1 (es) * 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0009468D0 (en) * 2000-04-17 2000-06-07 Vectura Ltd Improvements in or relating to formulations for use in inhaler devices
EP1296651B2 (en) * 2000-06-27 2019-07-17 Vectura Limited Method of making particles for use in a pharmaceutical composition

Also Published As

Publication number Publication date
GB2363988A (en) 2002-01-16
EP2272508B1 (en) 2020-03-25
PT1274406E (pt) 2007-01-31
SA01220062B1 (ar) 2006-11-05
NO20024973D0 (no) 2002-10-16
CZ20023437A3 (cs) 2003-02-12
EP2272508A3 (en) 2012-01-18
EP1276473A2 (en) 2003-01-22
WO2001078693A3 (en) 2002-01-17
ATE377416T1 (de) 2007-11-15
US20030180227A1 (en) 2003-09-25
HUP0300593A3 (en) 2006-07-28
PL204213B1 (pl) 2009-12-31
CN1424909A (zh) 2003-06-18
DZ3315A1 (fr) 2001-10-25
EP2272508A2 (en) 2011-01-12
GB2363987A (en) 2002-01-16
US20030175214A1 (en) 2003-09-18
US7223748B2 (en) 2007-05-29
CA2406201C (en) 2011-03-22
MXPA02010218A (es) 2003-05-23
WO2001078694A2 (en) 2001-10-25
SI1719505T1 (sl) 2011-12-30
DE60123031D1 (de) 2006-10-26
MY129384A (en) 2007-03-30
CA2406119C (en) 2009-07-07
PL358640A1 (en) 2004-08-09
EP1276472B1 (en) 2006-12-20
PL204251B1 (pl) 2009-12-31
ATE513542T1 (de) 2011-07-15
ES2292576T3 (es) 2008-03-16
AU2001258343A1 (en) 2001-10-30
PL359289A1 (en) 2004-08-23
CA2406119A1 (en) 2001-10-25
PT1276472E (pt) 2007-02-28
HU230464B1 (hu) 2016-07-28
GB0109432D0 (en) 2001-06-06
HUP0300499A2 (en) 2003-07-28
ATE521340T1 (de) 2011-09-15
US8182791B2 (en) 2012-05-22
NO20024971L (no) 2002-12-17
EE200200593A (et) 2004-04-15
DE60131265T2 (de) 2008-03-06
SK14912002A3 (sk) 2003-03-04
NO342999B1 (no) 2018-09-24
US6884794B2 (en) 2005-04-26
HUP1300117A2 (en) 2003-07-28
EP1719505A3 (en) 2007-07-18
CY1107315T1 (el) 2012-11-21
ATE339195T1 (de) 2006-10-15
ES2275669T3 (es) 2007-06-16
CA2406201A1 (en) 2001-10-25
HU229270B1 (en) 2013-10-28
US20120308613A1 (en) 2012-12-06
PE20011227A1 (es) 2002-01-07
AU4859501A (en) 2001-10-30
BR0110141A (pt) 2003-01-28
MXPA02010212A (es) 2004-06-29
EP1274406B1 (en) 2006-09-13
EE05257B1 (et) 2010-02-15
WO2001078693A2 (en) 2001-10-25
NO20024973L (no) 2002-12-16
NO336687B1 (no) 2015-10-19
PL358875A1 (en) 2004-08-23
JP2003530425A (ja) 2003-10-14
MA26892A1 (fr) 2004-12-20
DE60123031T2 (de) 2007-03-08
HU229797B1 (en) 2014-07-28
MXPA02010213A (es) 2005-07-01
CA2405767C (en) 2011-07-05
SK284248B6 (sk) 2004-12-01
DE60125344D1 (de) 2007-02-01
EP1719505B1 (en) 2011-08-24
EP1829533A2 (en) 2007-09-05
HUP0300490A2 (en) 2003-07-28
GB0109431D0 (en) 2001-06-06
WO2001078695A2 (en) 2001-10-25
DK1274406T3 (da) 2007-01-22
EP1719505A2 (en) 2006-11-08
AU784719B2 (en) 2006-06-01
HUP0300593A2 (hu) 2003-09-29
EP1829533B1 (en) 2011-06-22
DK1719505T3 (da) 2011-12-05
ES2272473T3 (es) 2007-05-01
NZ521887A (en) 2004-06-25
ATE348603T1 (de) 2007-01-15
US20050201950A1 (en) 2005-09-15
WO2001078694A3 (en) 2002-03-14
AU4858101A (en) 2001-10-30
NO20024980D0 (no) 2002-10-16
SI1274406T1 (sl) 2007-02-28
EP1276473B1 (en) 2007-11-07
KR20030069047A (ko) 2003-08-25
EP1276472A2 (en) 2003-01-22
DK1276472T3 (da) 2007-04-16
WO2001078695A3 (en) 2002-03-14
IL152306A0 (en) 2003-05-29
EP1274406A2 (en) 2003-01-15
BR0110139A (pt) 2002-12-31
DE60131265D1 (de) 2007-12-20
EP1829533A3 (en) 2007-10-31
NO20110885L (no) 2002-12-17
NO332025B1 (no) 2012-05-29
NO20024971D0 (no) 2002-10-16
TNSN01060A1 (fr) 2005-11-10
CA2405767A1 (en) 2001-10-25
PT1719505E (pt) 2011-10-24
BR0110301A (pt) 2003-12-30
DE60125344T2 (de) 2007-07-19
CZ301904B6 (cs) 2010-07-28
JP2012255035A (ja) 2012-12-27

Similar Documents

Publication Publication Date Title
NO20024980D0 (no) Farmasöytiske formuleringer for törrpulverinhalatorer i form av harde pelleter
JO2430B1 (en) Pharmaceutical formulas for dry powder inhalations in the form of solid pellets
JO3102B1 (ar) صيغ صيدلانية لوسائل استنشاق بها مسحوق جاف تشتمل على مكون فعال بقوة منخفضة الجرعة
HU220290B (hu) Inhaláló készülék és eljárás száraz por alakú aktív anyag inhalálására
Yang et al. Drug delivery performance of the mometasone furoate dry powder inhaler
AP2002002623A0 (en) Use of compounds in a dry powder inhaler
RU2338552C2 (ru) Фармацевтическая композиция для ингаляции
JP2002161030A (ja) 異なる粒径をもった混合粉体の吸入方法

Legal Events

Date Code Title Description
MK1K Patent expired